P-glycoprotein and chronic rhinosinusitis

Chronic rhinosinusitis (CRS) is a heterogeneous definition that includes different disease states that usually are associated with abnormal inflammatory responses. Besides being prevalent, the mechanisms involved in its pathogenesis are not clear and there are few therapeutic options with tolerable...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcel M. Miyake, Angela Nocera, Michelle M. Miyake
Format: article
Language:EN
Published: KeAi Communications Co., Ltd. 2018
Subjects:
Online Access:https://doaj.org/article/cd178f20e87f485f8b7af4520b10fc8a
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic rhinosinusitis (CRS) is a heterogeneous definition that includes different disease states that usually are associated with abnormal inflammatory responses. Besides being prevalent, the mechanisms involved in its pathogenesis are not clear and there are few therapeutic options with tolerable side effects. P-glycoprotein (P-gp) is an efflux pump responsible of extruding xenobiotics and cellular metabolites from multiple cell types. It has been widely studied in the cancer field, due to its ability to confer resistance to chemotherapy. It also promotes Type 2 helper T-cell polarizing cytokine secretion in CRS and may represent a potential target to differentiate subtypes of CRS and personalize treatment. This state-of-the-art review explores current knowledge on the participation of P-gp in the pathogenesis of CRS, the P-gp inhibition as a novel targeted therapeutic strategy and the exosomal P-gp test, a non-invasive biomarker that can represent an important advance in the field of rhinology. Keywords: Sinusitis, ATP binding cassette transporter, sub-family B, Verapamil, Exosomes, Nasal polyps, Nasal mucosa